D69.49, Other primary thrombocytopeniaICD-10-CM
No Prior Auth Required
Code is covered without prior authorization (high confidence)
CGS-J15-L40225, MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer
J15
CGS-J15-L34037, Flow Cytometry
J15
CGS-J15-L38070, MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
J15
CGS-J18-L40225, MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer
J18
Ask Backwork about documentation requirements, denial risks, or coverage in your state.
CGS-J18-L34037, Flow Cytometry
J18
CGS-J18-L38070, MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
J18
A57554, Billing and Coding: Immune Globulins
J5
WPS-J5-L38176, MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
J5
WPS-J5-L37205, Chemotherapy Drugs and their Adjuncts
J5
WPS-J5-L34771, Immune Globulins
J5
WPS-J5-L40277, MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer
J5
A55639, Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions
J5
A57878, Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
J5
NGS-J6-L39314, Off-Label Use of Intravenous Immune Globulin (IVIG)
J6
A56793, Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases
J6
NGS-J6-L40357, Molecular Pathology Procedures
J6
NGS-J6-L39297, Off-label Use of Rituximab and Rituximab Biosimilars
J6
NGS-J6-L37606, Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases
J6
NGS-J6-L35000, Molecular Pathology Procedures
J6
A56199, Billing and Coding: Molecular Pathology Procedures
J6